

Product Data Sheet

Product Name: XMU-MP-10

Cat. No.: GC79628

Chemical Properties

Cas. No. 2251132-02-0


Formula $C_{18}H_{14}BrN_5O$ M.Wt 396.24

Solubility DMSO: 4.17 mg/mL (10.52 mM); ultrasonic and warming and heat to 60°C) Storage Store at -20°C

General tips For obtaining a higher solubility, please warm the tube at 37 °C and shake it in the ultrasonic bath for a while. Stock solution can be stored below -20°C for several months.

Shipping Condition Evaluation sample solution: ship with blue ice All other available size: ship with RT, or blue ice upon request.

Structure



Background

XMU-MP-10 is a selective NEDD4 inhibitor with a K_D of 43.92 nM. XMU-MP-10 selectively inhibits NEDD4 auto-ubiquitination without affecting other ubiquitination activity, upregulates β -TrCP and results in YAP degradation without affecting NEDD4 protein expression. XMU-MP-10 exhibits significant in vivo efficacy in inhibiting TNBC tumor growth by enhancing CD8 + T cell infiltration. XMU-MP-10 enhances antitumor immune responses through the β -TrCP / YAP / ECM axis. XMU-MP-10 can be used for Triple-Negative Breast Cancer (TNBC) research [1].

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA

Product Data Sheet

In Vivo, XMU-MP-10 (25 mg/kg, i.v., daily for 14 days) is well tolerated in 4T1 cells induced-BALB/c mice but not in 4T1 cells-induced BALB/c-nu mice^[1]. XMU-MP-10 (25 mg/kg, i.v., daily for 14 days) has a crucial role for CD8⁺ T cells in tumor inhibition and influences the β -TrCP-YAP-ECM axis in EMT6 cells induced-BALB/c mice^[1]. XMU-MP-10 (25 mg/kg, i.v., daily for 14 days) enhances antitumor immune response by increasing intratumoral infiltration of CD8 cytotoxic T cells in a humanized immune system mice model^[1].

In Vitro, XMU-MP-10 interacts with the HECT domain of NEDD4 at residues Y604, Y605, and Y634^[1]. XMU-MP-10 (0.1-10000 μ M) binds specifically to WT NEDD4, but not to NEDD4 mutants at Y604A, Y605A, or Y634A^[1]. XMU-MP-10 (0.25-10 μ M, 1-12 h) significantly inhibits the polyubiquitination of NEDD4 in a dose-dependent manner, upregulates of β -TrCP and results YAP degradation in a dose and time-dependent manner without affecting NEDD4 protein expression in EMT6, 4T1, MDA-MB-231 and HCC38 cells^[1]. XMU-MP-10 (2-10 μ M, 4 h) selectively inhibits NEDD4 auto-ubiquitination without affecting the ubiquitination activity of the other tested E3 ligases in HEK-293T cell^[1].

References:

[1]. Su N, et al.,. Inhibiting NEDD4 in triple-negative breast cancer cells reprograms tumor immune microenvironment via the β -TrCP/YAP/ECM axis. Cell Rep Med. 2025 Oct 21;6(10):102420.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: (909) 407-4943 Fax: (626) 353-8530 E-mail: tech@glpbio.com

Address: 10292 Central Ave. #205, Montclair, CA, USA